AbbVie Stock News

President-elect Donald Trump's promise that Robert F Kennedy Junior (RFK Jr) will take on a “big role” in shaping health policy could be a positive for psychedelics given RKF Jr's well-documented support of this drug class, analysts at Jefferies believe. “RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development,” analysts wrote in a note to clients, noti...

Recent trial failures over at pharma giant AbbVie Inc have created a window of opportunity for competitor Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP), is analysts at UBS are to be believed. AbbVie stock took a $38 billion hit on Monday after the company revealed that Phase 2 trials of its emraclidine schizophrenia treatment have failed to meet their primary endpoint objectives.

AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda.

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal. [1] Emraclidine was developed by Cerevel Therapeutics, which AbbVie acquired for around $9 billion earlier this year.

I review both AbbVie and Pfizer's recent earnings reports via the window of dividends following Peter Lynch's wisdom. Lynch's insights into dividend stocks are often in the shadow of his reputation as a legendary growth investor. These insights, when overlooked, are an unfortunate loss for dividend investors.

AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. There are three significant reasons for optimism from here. However, the dividend yield is near its lowest point in six years; it may pay to wait for another dip.

AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction appears excessive and presents a buying opportunity. Dividend yield and robust drug pipeline are bullish going forward.

A splashy recent acquisition by the company might not be panning out.